Anthropic expands Claude's role across drug discovery and clinical research — Hardware, PCs and semiconductors

Anthropic is working with biotechnology and pharmaceutical partners to apply Claude to CAR T-cell design, antibody discovery, manufacturing documentation and clinical trial planning, reporting early experimental results and a Bristol Myers Squibb collaboration.

Anthropic is widening Claude's role in pharmaceutical research through collaborations with biotechnology developers intended to speed the creation of new medicines. In a new blog post, the company said it is examining scientific and administrative bottlenecks from molecular design to clinical trial preparation. The projects involve potential treatments for cancer, food allergies and rare muscular disorders, though most remain at experimental stages. Anthropic said the best way to identify and work through these bottlenecks is to get deeply involved in real drug programs.

At Generate Biomedicines, six scientists used Claude Code to modify a component of CAR T-cell therapy, which is traditionally used against blood cancers. Their work sought to create more room for genetic instructions that could help the treatment address solid tumours. The redesigned component was about 70% shorter, and laboratory experiments found that immune cells produced roughly ten times more receptors. The modified cells also destroyed cancer cells more effectively and maintained their activity for longer periods, according to the reported findings.

Divergence Labs used Claude to develop antibody candidates for a potential food-allergy treatment involving the immune molecule IgE. The system generated about 35,000 molecular designs within one month, producing potential molecules for both functions required by the proposed treatment. Initial experiments identified three designs capable of binding to IgE and another 20 capable of detaching it from immune cells. Three of those 20 designs appeared more effective than the standard medication at removing IgE from immune cells.

BigHat Biosciences combined Claude with automated laboratory equipment to improve two antibody fragments being considered for future medicines. Researchers manufactured and tested about 1,010 variations over ten weeks, examining binding strength, stability and unwanted molecular aggregation. The strongest cancer-targeting version bound its intended target more than 10 times as tightly and retained stability at temperatures 18°C higher than the original. The other fragment, intended for longer-lasting medicines, aggregated more than 100 times more slowly than its original version.

Enveda applied Claude to manufacturing documentation, which had consumed up to 75% of some chemists' working time. During an assessment spanning 1,061 pages, the system identified all 11 problems previously discovered by human reviewers, as well as seven additional issues. The approach reduced manual checking time by 89%, bringing the review process from more than 25 hours to under three.

Anthropic has also partnered with Bristol Myers Squibb to assess clinical study plans and estimate their chances of success. Michael Pourdehnad, the pharmaceutical company's senior vice president for early clinical development, said: "From a single prompt, Claude generated a robust initial analysis." He explained that this helped evaluate development options that would otherwise have required several days of work. The companies intend to extend their collaboration further, examining Claude's potential contribution to decisions during early clinical development.

Anthropic said working directly with drug developers helps identify weaknesses in its models and opportunities for improvement across scientific research. The company also intends to extend Claude's involvement through additional partnerships, research programs and tools for life-science organizations.

Sources: TechRadar.